MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  
HCP Resources  Psychiatry  

Patient Resources 
Bipolar  
Diabetes  
Schizophrenia  


Useful Websites

specialistinfo.com
details of 26,000 UK specialists

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

DoctorOnline
information for doctors

The Converter Site
metric and imperial conversion tool.
home > drug information > Kytril

Kytril


Company: SmithKline Beecham
Approval Status: Approved November 1997
Treatment for: nausea and vomiting associated with chemotherapy
Areas: Oncology; Pharmacology/Toxicology
Possible similar drugs: Kytril

| General Information | Clinical Results | Side Effects |


General Information

Other Useful Resources

A single 2 mg dose of Kytril (granisetron hydrochloride) has been approved for the treatment of nausea and vomiting associated with chemotherapy. Until now, the recommended dosage for Kytril tablets was one 1 mg tablet administered anytime within one hour before chemotherapy and a second 1 mg tablet 12 hours after the first. Now cancer patients can take Kytril tablets either once or twice daily to prevent nausea and vomiting associated with chemotherapy. Kytril, which is a 5-HT (subscript 3) receptor antagonist, is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.



< back to top

Clinical Results

This labeling change was based in part on results from a double-blind multicenter trial in which 697 patients were randomized to receive either a single 2 mg dose of Kytril tablets or one 1 mg Kytril tablet one hour prior to chemotherapy and another 1 mg tablet 12 hours after the first tablet was given. Investigators evaluated the percentage of patients who achieved a complete response (no vomiting, no moderate or severe nausea and no rescue medication) and the incidence of emesis and nausea. Patients receiving a single 2 mg dose of Kytril tablets achieved a 64 percent response rate versus 69 percent for patients receiving Kytril tablets twice daily. This difference was not statistically significant.



< back to top

Side Effects

Kytril tablets are well tolerated. The most frequently reported adverse events are headache, asthenia and constipation.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.






pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, Mexico Office: + 52 1998 2142733
© 2007 MediLexicon International Ltd. MediLexicon International Ltd